Diffuse gliomas are among the most common tumors of the central nervous system, with high morbidity and mortality and very limited therapeutic possibilities. The diffuse glioma are characterized by significant variability in terms of age at diagnosis, histological and molecular features, classification, ability to transform to a higher grade and/or to disseminate in the brain, response to treatment and patient outcome.

One of the main challenges in the management of diffuse gliomas is related to tumor heterogeneity within the same subgroup. Establishing an accurate tumor classification is of paramount importance for selecting personalized therapy or avoiding unnecessary treatment.

At present, the main diagnostic methods for detecting gliomas are based on histopathological features and mutation detection. Yet difficulties remain, due to tumor heterogeneity and sampling bias for tumors obtained from small biopsies. In particular, grade 2 (low-grade) and grade 3 (high-grade) gliomas cannot be easily distinguished, as intra-tumoral tumor grade heterogeneity is not uncommon in patients treated with extensive surgical resection. Another challenge in the field of gliomas is longitudinal monitoring of disease progression, which is currently mainly based on repeated brain Magnetic Resonance Imaging (MRI). New tools to detect tumor changes before the onset of imaging changes would be useful.

Several genetic, epigenetic, metabolic and immunological profiles have been established for gliomas. Recently, the world of RiboNucleic Acid (RNA) has emerged as a promising area to explore for cancer therapy, especially since the (re)discovery of RNA chemical modifications. To date, more than 150 types of post-transcriptional modifications have been reported on various RNA molecules. This complex landscape of chemical marks embodies a new, invisible code that governs the post-transcriptional fate of RNA: stability, splicing, storage, translation.

Diffuse gliomas are among the most common tumors of the central nervous system, with high morbidity and mortality and very limited therapeutic possibilities. Diffuse gliomas are characterized by great variability in terms of age at diagnosis, histological and molecular features, classification, ability to progress to a higher grade and/or to disseminate in the brain, response to treatment and patient outcome. One of the major challenges in the management of diffuse gliomas is related to the heterogeneity of tumor behavior within the same tumor subgroup. Although efforts have been made in recent decades to improve tumor characterization and classification, with the integration of molecular markers (e.g. Isocitrate DeHydrogenase (IDH) mutation), it remains difficult to predict treatment response and patient outcome at the individual level. Yet accurate tumor classification is of paramount importance in choosing personalized therapy or avoiding unnecessary treatments. At present, the main diagnostic methods for detecting gliomas are based on histopathological features, mutation detection or chromosome copy number variation.

However, difficulties remain, particularly with tumor classification, due to tumor heterogeneity and sampling bias for tumors obtained from small biopsies. In particular, grade 2 ("low-grade") and grade 3 ("high-grade") gliomas cannot be easily distinguished, as intratumoral tumor grade heterogeneity is not uncommon in patients treated with extensive surgical resection. Another challenge posed by gliomas is longitudinal monitoring of disease progression, which currently relies mainly on repeated brain MRI scans, with no return to the tumor itself due to the difficulty of obtaining new tumor samples in this setting. New tools to detect tumor changes in plasma, before imaging changes occur, would be useful. However, circulating markers present a real challenge, as the detection of markers readily used in other cancer types (e.g. circulating free DNA and circulating tumor cells) is hampered by a lack of sensitivity in gliomas.

Several genetic, epigenetic, metabolic and immunological profiles have been established in gliomas, considerably expanding the knowledge of the biological characteristics of these tumors and helping to identify potential treatments. Recently, the world of RNA has emerged as a promising area to explore for cancer therapy, particularly since the (re)discovery of chemical modifications of RNA (epitranscriptomics). To date, over 150 types of post-transcriptional modification have been reported on various RNA molecules. This landscape complex of chemical marks embodies a new, invisible code that governs the post-transcriptional fate of RNA: stability, splicing, storage, translation. Importantly, RNA epigenetics has emerged as a new layer of gene expression regulation in healthy tissues as well as in other pathologies such as cancer.

Chemical markers are associated with cancer evolution and adaptation, as well as with response to conventional therapies. Based on these observations, it is envisaged that: (1) the RNA epigenetic landscape evolves with cancer progression, establishing a "chemical signature" that could be exploited for diagnostic, prognostic and treatment response prediction purposes; (2) several chemical marks are not mere "transient" alterations but rather "driving" alterations of the tumorigenic process; (3) unlike unmodified nucleosides, modified nucleosides are preferentially excreted as metabolic end products in urine after circulating in the blood. Consequently, altered RNA markers in cancerous tissues can be detected in urine and blood and exploited for diagnostic purposes. An original approach recently published combines multiplex analysis of RNA marks by mass spectrometry with bioinformatics and machine learning. Using total RNA samples extracted from an existing cohort of patients (59 grade 2, 3 and 4 gliomas; 19 non-cancerous control samples), a first "chemical signature" capable of predicting glioma grade with remarkable efficiency and accuracy has been established.

N6, 2'-O-dimethyladenosine (m6Am), the most up-regulated marker in glioblastoma (GBM), is a driver of colorectal cancer aggressiveness. Located at the 5' end of messenger RiboNucleic Acid (mRNA), m6Am can influence mRNA stability and translation efficiency. This chemical tag is deposited by the Phosphorylated Carboxyl terminal domain Interacting Factor 1 (PCIF1), also known as CAPAM (PCIF1/CAPAM) methyltransferase (writer) and removed by the Fat mass and Obesity-associated protein (FTO) demethylase (eraser). FTO is down-regulated in colorectal cancer stem cells (CSCs), consistent with m6Am accumulation. High levels of m6Am significantly enhance CSC properties such as in vivo tumor initiation and chemoresistance, without significant changes to the transcriptome. This aggressive phenotype can be reversed by inhibition of PCIF1, demonstrating the potential of targeting epigenetic RNA effectors. The preliminary data on patient-derived glioma cell lines suggest a similar mechanism in glioma, where down-regulation of FTO promotes sphere-forming capacity in suspension culture of GBM stem cells.

(3) A method has been established to detect RNA markers in plasma samples that yielded favorable results after analysis of plasma samples from a colorectal cancer cohort. The same process was used to obtain preliminary data by analyzing plasma samples from grade 2 glioma patients vs. healthy donors. This experiment confirmed the possibility of detecting and quantifying 20 circulating nucleosides in blood. Significant changes were demonstrated between healthy donors and glioma patient samples for some of the circulating nucleosides. Some were up-regulated (e.g. n6,2'-O-dimethyladenosine (m6Am), 1-methylguanosine (m1G)) while others were down-regulated (e.g. adenosine (A), 5-methoxycarbonylmethyl-2-thiouridine (mcm5s2U)). Importantly, not all the tagged RNAs detected were altered (e.g. N1-methyladenosine (m1A); 5-methylcytosine (m5C)). If confirmed by a larger cohort, these changes could constitute an epitranscriptomics-based circulating signature for early disease detection. This preliminary experience reinforces the interest in m6Am.

Finally, changes were also observed in the serum of the same patients compared to healthy donor subjects, but from other nucleosides. This underlines the importance of studying circulating markers in blood for the diagnosis of gliomas.

Inclusion Criteria:

• Male / female over 18 years of age,
• Surgery (tumor resection) scheduled at Montpellier University Hospital for suspected, diffuse glioma, confirmed on tissue sample: IDH mutated grade 2 glioma (excluding tumors with a focus of grade 3 or 4 glioma), IDH mutated grade 3 glioma or GBM, IDH wild-type,
• No history of treatment (surgery, radiotherapy or chemotherapy) for glioma,
• Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures,
• Patient has given express written informed consent prior to any study procedure,
• Patient affiliated to a French health insurance.

Exclusion Criteria:

• Patients whose regular follow-up is impossible for psychological, family, social or geographical reasons,
• Patients under guardianship, curatorship or safeguard of justice,
• Pregnant and/or breast-feeding patient (information gathered from the medical file, as part of the patient's standard medical care and follow-up),
• Histo-molecular diagnosis of grade 4 IDH-mutated astrocytoma,
• For grade 2 gliomas, presence within the tumor of one or more higher-grade sites (3 or 4).

Participant data will be made available on request and with the completion of a contract between the sponsor and the requester.

Access to study data upon written detailed request sent to the institute of Montpellier Cancer (ICM), following publication and until 5 years after publication of summary data.

The data shared will be limited to that required for independent mandated verification of the published results, the applicant will need authorization from ICM for personal access, and data will only be transferred after signing of a data access agreement.